The salary figures of medical representatives have been announced, and they are still rising!

The average salary of employees in foreign-funded pharmaceutical companies is the highest at 120,072 yuan, while that of private pharmaceutical companies is the lowest at 76,004 yuan; it is worth noting that the average annual salary of sales posts is 129,298 yuan—in the entire pharmaceutical industry, the salary level of pharmaceutical representatives is still Stay at the forefront and maintain a certain increase.

Recently, according to the Securities Daily, among the 288 companies with year-on-year data in the pharmaceutical industry in 2018, 199 executive compensation expenditure items increased, of which 126 companies’ executive compensation increased by more than 50%, and 14 companies’ chairman compensation The annual salary of the chairman of 35 companies is the same as that in 2017.

Among them, there are 4 chairmen whose salaries exceed 10 million. They are Li Ge from WuXi AppTec, Li Xiting from Mindray Medical, Chen Qiyu from Fosun Pharma and Cui Jinhai from Ogilvy Medical. Their annual salaries are 17.646 million and 17.323 million respectively. million, 14.2504 million and 12.6959 million yuan. The lowest is Wang Minghui of Yunnan Baiyao, whose annual salary is only 27,600 yuan.

As far as general managers are concerned, the salaries of general managers of 105 listed companies exceed one million yuan. WuXi AppTec, Mindray Medical and Fosun Pharma opened up the gap with the fourth place with absolute advantages. The salaries of their general managers were 17.646 million and 16.6391 million respectively. million and 8.1382 million.

A few days ago, the editor released the per capita salary of employees of 23 pharmaceutical companies.

Minnet

Some readers said in the backstage of Cyberland: Most people’s salaries are “averaged”—the high salaries of the executive team and the high salaries of the salesmen prove that the salaries of the vast majority of people in the company are averaged .

What's more, the nominal salary is high, and the salary in hand is low. Deductions such as five insurances and one housing fund, personal income tax, disability insurance, trade union funds, various surcharges, and company human resource costs.

For example, a reader revealed that the total salary of twelve executives of a certain group is 24 million, and the total salary of more than 2,000 employees is 27 million. On average, it does not mean much.

Therefore, we need a salary analysis with more detailed data.

The management consulting firm Jones Day and Park Letters, based on data such as the salary level, salary increase, salary structure, turnover rate and other data of the pharmaceutical company industry, came up with a report on the salary survey data of the pharmaceutical industry.

The report shows that among the average wages and salary increases of the enterprise series in 2018, the average wages and increases of R&D employees are the highest, which are 143,611 yuan and 13.4%, respectively, followed by the average wages of sales and marketing employees, which are 129,298 yuan and 103,722 yuan. yuan, with an increase of 7.5% and 8%.

This means that, compared with other positions, the salary level of medical representatives is at the forefront, and it still maintains a certain increase.

From the perspective of industry subdivision type, the average salary and growth rate of pharmaceutical research and development is the highest, the average salary of chemical raw materials and preparations is the lowest, only 80,837 yuan, and the average salary of pharmaceutical business & retail is in the middle, 95,924 yuan.

In addition, the report also announced the level of salary in each subdivided field. The level of salary distribution of directors, supervisors, commissioners and other positions is impressively listed, and the basic trend is also consistent with the average salary above.

From the perspective of the nature of the company, the average salary of employees in foreign-funded pharmaceutical companies is the highest, reaching 120,072 yuan, while private pharmaceutical companies have the lowest, only 76,004 yuan.

All along, the treatment of foreign companies is better. Taking the sales post as an example, the data shows that the upper limit of Pfizer's general generation is 11k, the upper limit of high-level generation is 18k, and the subsidy is 1500+15% of the salary, 12 salary; Salary; AbbVie’s Pudai 6k+, Gaodai 8k+, supervisor 13k, region 15k, subsidy 2k, 13 salary.

The level of average salary will also have a certain impact on the turnover rate. After analyzing the voluntary turnover rate of enterprises of different natures, the report found that the voluntary turnover rate of employees in private enterprises is the highest at 17.8%, followed by joint ventures at 14.2%. The lowest is a state-owned enterprise, and the voluntary turnover rate is only 6.5%.

From the perspective of positions, the overall turnover rate of sales posts is relatively high. Therefore, the turnover rate of pharmaceutical representatives of private pharmaceutical companies is generally high.

Previously, medical crab data showed that the recruitment of medical representatives reached a new low: the market release of medical representative/promotion/sales positions showed a continuous downward trend of fluctuations. From the perspective of the overall position release trend, the market demand for pharmaceutical promotion positions has sharply increased after 2017 Decline, and by the end of 2018, reach the trough of job demand.

However, as can be seen from the salary report above, the salary increase of sales posts in pharmaceutical companies still maintains an upward trend; in the entire pharmaceutical industry, the salary level of pharmaceutical representatives remains at the forefront.

It can be seen that the profession of medical representative still has vitality, but needs transformation and survival of the fittest.

We all know that the professional definition of a medical representative is "a professional engaged in drug information transmission, communication, and feedback on behalf of a pharmaceutical manufacturer", but for a long time in the past, a medical representative once became a "kickback" and "sales with gold" synonymous with.

There have been opinions in the industry that: now the relevant departments have higher and higher compliance requirements, the reduction of market expenses has led to the reduction of rebates, and the pharmaceutical channels have continued to sink. Pharmaceutical companies should turn to the integration of elite representatives or agents with low cost and wide coverage. marketing model.

In this context, as long as medical representatives continue to accumulate their expertise and evolve themselves to meet the functional needs of their positions and create value in their positions, they can adapt to the ever-growing market demand for talents.